2026-07-18T18:32:00Zhttps://riubu.ubu.es/oai/requestoai:riubu.ubu.es:10259/119192026-07-17T00:05:26Zcom_10259_11209com_10259_5086com_10259_2604col_10259_11210
Sanz-Solas, Antonio
e7bed634-9e5c-498e-b63d-ecd8df4a94a0
500
Labrador, Jorge
dc9309b6-a772-4f21-a5af-90fe29e9645a
500
Alcaraz, Raquel
f37b3220-2c62-4524-ab2c-60d6a8de878a
500
Cuevas, Beatriz
60bfcf08-9e03-4d6f-a2a3-4a190c3c7ada
500
Vinuesa, Raquel
07d4511c-c1cc-4ccf-8478-c1518b5994f3
500
Cuevas, María Victoria
19c28c34-6a9d-4945-9bde-9405419ef305
500
Saiz-Rodríguez, Miriam
3419cbb9-ca85-411e-b179-3821e40f7b8a
500
2026-07-16T11:27:01Z
2026-07-16T11:27:01Z
2023-04
2075-4426
https://hdl.handle.net/10259/11919
10.3390/jpm13040695
Multiple myeloma (MM) is a hematological neoplasm for which different chemotherapy treatments are used with several drugs in combination. One of the most frequently used drugs for the treatment of MM is the proteasome inhibitor bortezomib. Patients treated with bortezomib are at increased risk for thrombocytopenia, neutropenia, gastrointestinal toxicities, peripheral neuropathy, infection, and fatigue. This drug is almost entirely metabolized by cytochrome CYP450 isoenzymes and transported by the efflux pump P-glycoprotein. Genes encoding both enzymes and transporters involved in the bortezomib pharmacokinetic pathway are highly polymorphic. The response to bortezomib and the incidence of adverse drug reactions (ADRs) vary among patients, which could be due to interindividual variations in these possible pharmacogenetic biomarkers. In this review, we compiled all pharmacogenetic information relevant to the treatment of MM with bortezomib. In addition, we discuss possible future perspectives and the analysis of potential pharmacogenetic markers that could influence the incidence of ADR and the toxicity of bortezomib. It would be a milestone in the field of targeted therapy for MM to relate potential biomarkers to the various effects of bortezomib on patients.
A.S.-S. contract was funded by Fundación hna, 2nd edition of the Scientific Health Research Award. M.S.-R. contract was supported by Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation, through the Sara Borrell Program (CD21/00022).
eng
MDPI
Journal of Personalized Medicine. 2023, V.13, n. 4, art. 695
https://doi.org/10.3390/jpm13040695
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
Multiple myeloma
Bortezomib
Toxicity
Efficacy
Pharmacogenetic biomarkers
Farmacogenómica
Pharmacogenomics
Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Journal of Personalized Medicine
13
4
THUMBNAIL
Sanz-JPM_2023.pdf.jpg
Sanz-JPM_2023.pdf.jpg
IM Thumbnail
image/jpeg
3337
https://riubu.ubu.es/bitstream/10259/11919/4/Sanz-JPM_2023.pdf.jpg
f6d8c2015c6a2246443a63a17f5421b4
MD5
4
LICENSE
license.txt
license.txt
text/plain; charset=utf-8
1362
https://riubu.ubu.es/bitstream/10259/11919/3/license.txt
5d013bfa6e473ff0db22cd82a4d71a70
MD5
3
CC-LICENSE
license_rdf
license_rdf
application/rdf+xml; charset=utf-8
908
https://riubu.ubu.es/bitstream/10259/11919/2/license_rdf
0175ea4a2d4caec4bbcc37e300941108
MD5
2
ORIGINAL
Sanz-JPM_2023.pdf
Sanz-JPM_2023.pdf
application/pdf
661895
https://riubu.ubu.es/bitstream/10259/11919/1/Sanz-JPM_2023.pdf
074837fca50048bce80547a048360f62
MD5
1
10259/11919
oai:riubu.ubu.es:10259/11919
2026-07-17 02:05:26.899
Repositorio Institucional de la Universidad de Burgos
bubrep@ubu.es
RWwgYXV0b3IgY29tbyDDum5pY28gdGl0dWxhciBkZSBsb3MgZGVyZWNob3MgZGUgcHJvcGllZGFkIGludGVsZWN0dWFsIGRlIGxhIG9icmEsIG8gZGlzcG9uaWVuZG8gZGUgbG9zIGRlYmlkb3MgcGVybWlzb3MgZGUgbG9zIG90cm9zIHRpdHVsYXJlcywgc2kgbG9zIGh1YmllcmEsIHkgZW4gdmlydHVkIGRlIGxvcyBkZXJlY2hvcyBxdWUgbGUgY29uZmllcmUgbGEgbGVnaXNsYWNpw7NuIHZpZ2VudGUgc29icmUgcHJvcGllZGFkIGludGVsZWN0dWFsIHkgZGVyZWNob3MgZGUgYXV0b3IsIApBVVRPUklaQSBhIGxhIFVuaXZlcnNpZGFkIGRlIEJ1cmdvcyBhIGRpZnVuZGlyLCBkZSBtYW5lcmEgZ3JhdHVpdGEsIGVsIGNvbnRlbmlkbyBkZSBsb3MgYXJjaGl2b3MgZGlnaXRhbGVzIHF1ZSBjb3JyZXNwb25kZW4gYWwgZG9jdW1lbnRvIGRlc2NyaXRvIGFudGVyaW9ybWVudGUsIGNvbiBjYXLDoWN0ZXIgbm8gZXhjbHVzaXZvIHkgZGUgbWFuZXJhIHDDumJsaWNhIGVuIGFjY2VzbyBhYmllcnRvIGEgdHJhdsOpcyBkZSBJbnRlcm5ldCwgcGFyYSBsbyBxdWUgbGEgQmlibGlvdGVjYSBwcm9jZWRlcsOhIGEgYXJjaGl2YXJsb3MgZW4gZWwgUmVwb3NpdG9yaW8gSW5zdGl0dWNpb25hbC4gQXNpbWlzbW8gYXV0b3JpemEgYSBsYSBVbml2ZXJzaWRhZCBkZSBCdXJnb3MgYSByZWFsaXphciBsYXMgdHJhbnNmb3JtYWNpb25lcyBuZWNlc2FyaWFzIGRlIGZvcm1hdG8sIG5vIGRlIGNvbnRlbmlkbywgcGFyYSBnYXJhbnRpemFyIGxhIHByZXNlcnZhY2nDs24geSBlbCBhY2Nlc28gZW4gZWwgZnV0dXJvLgoKRWwgYXV0b3IgZGlzcG9uZSwgZW4gdG9kbyBjYXNvLCBkZWwgZGVyZWNobyBhIHJldm9jYXIgZXN0YSBhdXRvcml6YWNpw7NuLgoKTGEgY2VzacOzbiBkZSBkZXJlY2hvcyBkZSBlc3RhIG9icmEgc2UgZW5jdWVudHJhIHN1amV0YSBhIGxhIGxlZ2lzbGFjacOzbiB2aWdlbnRlIHNvYnJlIHByb3BpZWRhZCBpbnRlbGVjdHVhbCB5IGRlcmVjaG9zIGRlIGF1dG9yLiBTdSBkaWZ1c2nDs24gZW4gZWwgUmVwb3NpdG9yaW8gc2Vyw6EgYmFqbyBsYSBtb2RhbGlkYWQgZGUgbGljZW5jaWEgQ3JlYXRpdmUgQ29tbW9ucyBvIGVxdWl2YWxlbnRlOiByZWNvbm9jaW1pZW50byDigJMgdXNvIG5vIGNvbWVyY2lhbCDigJMgc2luIG9icmEgZGVyaXZhZGEsIHBvciBsYSBxdWUgc2UgcGVybWl0ZSBoYWNlciBjb3BpYSwgZGlzdHJpYnVpciB5IGNvbXVuaWNhciBww7pibGljYW1lbnRlIGxhIG9icmEgc2llbXByZSBxdWUgc2UgY2l0ZSBhbCBhdXRvciwgZWwgdXNvIHF1ZSBzZSBoYWdhIGRlIGVsbGEgc2VhIG5vIGNvbWVyY2lhbCB5IG5vIHNlIGNyZWVuIG9icmFzIGRlcml2YWRhcyBhIHBhcnRpciBkZSBsYSBvcmlnaW5hbC4K